Tislelizumab plus chemo before surgery for head and neck cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of head and neck cancer called squamous cell carcinoma that can be surgically removed.
- Your cancer is stage III or IVB, and your doctor believes it can be completely removed with surgery.
- You have not had any prior treatment for this cancer.
- You are healthy enough for daily activities with an ECOG score of 0 to 2.
- Your major organs (bone marrow, kidneys, liver) are working well based on blood tests.
- You agree to use effective birth control during the study and for 6 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
This Phase 2 study tests whether giving low-dose radiation before surgery—along with chemotherapy and an immunotherapy drug—can work better and be safe for treating locally advanced head and neck squamous cell cancer. It may help shrink tumors before surgery and reduce the chance of the cancer coming back.
This Phase 2 study tests whether tislelizumab (an immunotherapy) combined with chemotherapy works better for locally advanced head and neck squamous cell cancer. It aims to improve cancer control when the tumor is large and has not spread to distant organs.
This Phase 2 trial tests tirelizumab combined with two chemotherapy medicines before surgery for certain head and neck squamous cell cancers. It aims to shrink the tumor and improve outcomes after the operation.
Hear when a new Head &Amp; Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.